86 related articles for article (PubMed ID: 2440564)
1. Pyrazoloacridines, a new class of anticancer agents with selectivity against solid tumors in vitro.
Sebolt JS; Scavone SV; Pinter CD; Hamelehle KL; Von Hoff DD; Jackson RC
Cancer Res; 1987 Aug; 47(16):4299-304. PubMed ID: 2440564
[TBL] [Abstract][Full Text] [Related]
2. Pyrimido [4,5,6-kl] acridines, a new class of potential anticancer agents. Synthesis and biological evaluation.
Antonini I; Polucci P; Cola D; Bontemps-Gracz M; Pescalli N; Menta E; Martelli S
Anticancer Drug Des; 1996 Jun; 11(4):339-49. PubMed ID: 8679056
[TBL] [Abstract][Full Text] [Related]
3. Activity of the pyrazoloacridines against multidrug-resistant tumor cells.
Sebolt J; Havlick M; Hamelehle K; Nelson J; Leopold W; Jackson R
Cancer Chemother Pharmacol; 1989; 24(4):219-24. PubMed ID: 2752501
[TBL] [Abstract][Full Text] [Related]
4. Comparative molecular field analysis of in vitro growth inhibition of L1210 and HCT-8 cells by some pyrazoloacridines.
Horwitz JP; Massova I; Wiese TE; Wozniak AJ; Corbett TH; Sebolt-Leopold JS; Capps DB; Leopold WR
J Med Chem; 1993 Nov; 36(23):3511-6. PubMed ID: 8280289
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig HH; Kelland LR; Double JA; Bibby MC; Hendriks HR
Anticancer Res; 2004; 24(2B):907-19. PubMed ID: 15161044
[TBL] [Abstract][Full Text] [Related]
6. (R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]- bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro.
Kirshenbaum MR; Chen SF; Behrens CH; Papp LM; Stafford MM; Sun JH; Behrens DL; Fredericks JR; Polkus ST; Sipple P
Cancer Res; 1994 Apr; 54(8):2199-206. PubMed ID: 8174127
[TBL] [Abstract][Full Text] [Related]
7. Rational design, synthesis, and biological evaluation of bis(pyrimido[5,6,1-de]acridines) and bis(pyrazolo[3,4,5-kl]acridine-5-carboxamides) as new anticancer agents.
Antonini I; Polucci P; Magnano A; Sparapani S; Martelli S
J Med Chem; 2004 Oct; 47(21):5244-50. PubMed ID: 15456268
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents.
Gamage SA; Spicer JA; Atwell GJ; Finlay GJ; Baguley BC; Denny WA
J Med Chem; 1999 Jul; 42(13):2383-93. PubMed ID: 10395479
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological and toxicological aspects of new imidazoacridinone antitumor agents.
Berger B; Marquardt H; Westendorf J
Cancer Res; 1996 May; 56(9):2094-104. PubMed ID: 8616856
[TBL] [Abstract][Full Text] [Related]
10. Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome.
Vispé S; Vandenberghe I; Robin M; Annereau JP; Créancier L; Pique V; Galy JP; Kruczynski A; Barret JM; Bailly C
Biochem Pharmacol; 2007 Jun; 73(12):1863-72. PubMed ID: 17391647
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removal.
Adjei AA; Budihardjo II; Rowinsky EK; Kottke TJ; Svingen PA; Buckwalter CA; Grochow LB; Donehower RC; Kaufmann SH
Clin Cancer Res; 1997 May; 3(5):761-70. PubMed ID: 9815747
[TBL] [Abstract][Full Text] [Related]
12. Anthrapyrazoles, a new class of intercalating agents with high-level, broad spectrum activity against murine tumors.
Leopold WR; Nelson JM; Plowman J; Jackson RC
Cancer Res; 1985 Nov; 45(11 Pt 1):5532-9. PubMed ID: 4053027
[TBL] [Abstract][Full Text] [Related]
13. Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice.
LoRusso P; Wozniak AJ; Polin L; Capps D; Leopold WR; Werbel LM; Biernat L; Dan ME; Corbett TH
Cancer Res; 1990 Aug; 50(16):4900-5. PubMed ID: 2165850
[TBL] [Abstract][Full Text] [Related]
14. Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II.
Adjei AA; Charron M; Rowinsky EK; Svingen PA; Miller J; Reid JM; Sebolt-Leopold J; Ames MM; Kaufmann SH
Clin Cancer Res; 1998 Mar; 4(3):683-91. PubMed ID: 9533538
[TBL] [Abstract][Full Text] [Related]
15. The role of structural factors in the kinetics of cellular uptake of pyrazoloacridines and pyrazolopyrimidoacridines: implications for overcoming multidrug resistance towards leukaemia K562/DOX cells.
Tarasiuk J; Majewska E; Seksek O; Rogacka D; Antonini I; Garnier-Suillerot A; Borowski E
Biochem Pharmacol; 2004 Nov; 68(9):1815-23. PubMed ID: 15450947
[TBL] [Abstract][Full Text] [Related]
16. A novel class of achiral seco-analogs of CC-1065 and the duocarmycins: design, synthesis, DNA binding, and anticancer properties.
Kupchinsky S; Centioni S; Howard T; Trzupek J; Roller S; Carnahan V; Townes H; Purnell B; Price C; Handl H; Summerville K; Johnson K; Toth J; Hudson S; Kiakos K; Hartley JA; Lee M
Bioorg Med Chem; 2004 Dec; 12(23):6221-36. PubMed ID: 15519165
[TBL] [Abstract][Full Text] [Related]
17. 8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
Stefańska B; Dzieduszycka M; Bontemps-Gracz MM; Borowski E; Martelli S; Supino R; Pratesi G; De Cesare M; Zunino F; Kuśnierczyk H; Radzikowski C
J Med Chem; 1999 Sep; 42(18):3494-501. PubMed ID: 10479282
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of DMP 840: a novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivity.
McRipley RJ; Burns-Horwitz PE; Czerniak PM; Diamond RJ; Diamond MA; Miller JL; Page RJ; Dexter DL; Chen SF; Sun JH
Cancer Res; 1994 Jan; 54(1):159-64. PubMed ID: 8261436
[TBL] [Abstract][Full Text] [Related]
19. Antitumor polycyclic acridines. Part 12. Physical and biological properties of 8,13-diethyl-6-methylquino[4,3,2-kl]acridinium iodide: a lead compound in anticancer drug design.
Missailidis S; Stanslas J; Modi C; Ellis MJ; Robins RA; Laughton CA; Stevens MF
Oncol Res; 2002; 13(3):175-89. PubMed ID: 12549627
[TBL] [Abstract][Full Text] [Related]
20. CGP 48664, a new S-adenosylmethionine decarboxylase inhibitor with broad spectrum antiproliferative and antitumor activity.
Regenass U; Mett H; Stanek J; Mueller M; Kramer D; Porter CW
Cancer Res; 1994 Jun; 54(12):3210-7. PubMed ID: 8205541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
